Eccles M, Bradshaw C. Use of secondary prophylaxis against myocardial infarction in the north of England.
BMJ (CLINICAL RESEARCH ED.) 1991;
302:91-2. [PMID:
1671652 PMCID:
PMC1668878 DOI:
10.1136/bmj.302.6768.91]
[Citation(s) in RCA: 38] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
OBJECTIVE
To record the use of secondary prophylactic drugs in patients discharged from hospital having had a myocardial infarction.
DESIGN
Prospective postal questionnaire survey of a random one in two sample of general practitioners in the region.
SETTING
The nine family practitioner committee areas within the Northern Regional Health Authority.
PATIENTS
Patients who had had a myocardial infarction and were discharged to their general practitioner.
MAIN OUTCOME MEASURE
Whether beta blockers or aspirin, or both, were given on discharge.
RESULTS
Of 267 patients, 158 (59%) were treated suboptimally in that they did not receive a secondary prophylactic drug to which they had no contraindication. For most patients this entailed underuse of one drug, but 17 (6%) of patients received no treatment. beta Blockers were 2.5 times less likely to be used than aspirin. Treatment was not associated with the age or sex of the patient, risk of further infarction, or hospital of discharge.
CONCLUSIONS
Secondary prophylaxis after myocardial infarction is practised haphazardly. It should be offered to all patients who can tolerate it, after a trial period to assess any side effects of the drugs if necessary.
Collapse